ログイン

3

3
82問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Which of the following platelet aggregating agents demonstrates a monophasic aggregation curve when used in optimal concentration? A. Thrombin B. Collagen C. Adenosine diphosphate (ADP) D. Epinephrine

    B. Collagen

  • 2

    The APTT is sensitive to a deficiency of which clotting factor? A. Factor VII B. Factor X C. PF3 D. Calcium

    B. Factor X

  • 3

    Which test result would be normal in a patient with dysfibrinogenemia? A. Thrombin time B. APTT C. PT D. Immunologic fibrinogen level

    D. Immunologic fibrinogen level

  • 4

    A patient with a prolonged PT is given intravenous vitamin K. The PT corrects to normal after 24 hours. What clinical condition most likely caused these results? A. Necrotic liver disease B. Factor X deficiency C. Fibrinogen deficiency D. Obstructive jaundice

    D. Obstructive jaundice

  • 5

    Which factor deficiency is associated with a prolonged PT and APTT? A. X B. VIII C. IX D. XI

    A. X

  • 6

    A prolonged APTT is corrected with factor VIII– deficient plasma but not with factor IX–deficient plasma. Which factor is deficient? A. V B. VIII C. IX D. X

    C. IX

  • 7

    6. Which of the following is a characteristic of classic hemophilia A? A. Prolonged bleeding time B. Autosomal recessive inheritance C. Mild to severe bleeding episodes D. Prolonged PT

    C. Mild to severe bleeding episodes

  • 8

    Refer to the following results: PT = prolonged APTT = prolonged Platelet count = decreased Which disorder may be indicated? A. Factor VIII deficiency B. von Willebrand’s disease C. DIC D. Factor IX deficiency

    C. DIC

  • 9

    Which of the following is a predisposing condition for the development of DIC? A. Adenocarcinoma B. Idiopathic thrombocytopenic purpura (ITP) C. Post-transfusion purpura (PTP) D. Heparin-induced thrombocytopenia (HIT)

    A. Adenocarcinoma

  • 10

    Factor XII deficiency is associated with: A. Bleeding episodes B. Epistaxis C. Decreased risk of thrombosis D. Increased risk of thrombosis

    D. Increased risk of thrombosis

  • 11

    The following results were obtained on a patient: normal platelet count and function, normal PT, and prolonged APTT. Which of the following disorders is most consistent with these results? A. Hemophilia A B. Bernard–Soulier syndrome C. von Willebrand’s disease D. Glanzmann’s thrombasthenia

    A. Hemophilia A

  • 12

    The following laboratory results were obtained from a 40-year-old woman: PT = 20 sec; APTT = 50 sec; thrombin time = 18 sec. What is the most probable diagnosis? A. Factor VII deficiency B. Factor VIII deficiency C. Factor X deficiency D. Hypofibrinogenemia

    D. Hypofibrinogenemia

  • 13

    When performing a factor VIII activity assay, a patient’s plasma is mixed with: A. Normal patient’s plasma B. Factor VIII deficient plasma C. Plasma with a high concentration of factor VIII D. Normal control plasma

    B. Factor VIII deficient plasma

  • 14

    The most suitable product for treatment of factor VIII deficiency is: A. Fresh frozen plasma B. Factor VIII concentrate C. Prothrombin complex concentrate D. Factor V Leiden

    C. Prothrombin complex concentrate

  • 15

    Which of the following is associated with an abnormal platelet aggregation test? A. Factor VIII deficiency B. Factor VIII inhibitor C. Lupus anticoagulant D. Afibrinogenemia

    D. Afibrinogenemia

  • 16

    Refer to the following results: PT = normal APTT = prolonged Bleeding time= increased Platelet count = normal Platelet aggregation to ristocetin = abnormal Which of the following disorders may be indicated? A. Factor VIII deficiency B. DIC C. von Willebrand’s disease D. Factor IX deficiency

    C. von Willebrand’s disease

  • 17

    Which results are associated with hemophilia A? A. Prolonged APTT, normal PT B. Prolonged PT and APTT C. Prolonged PT, normal APTT D. Normal PT and APTT

    A. Prolonged APTT, normal PT

  • 18

    Fibrin monomers are increased in which of the following conditions? A. Primary fibrinolysis B. DIC C. Factor VIII deficiency D. Fibrinogen deficiency

    B. DIC

  • 19

    Which of the following is associated with multiple factor deficiencies? A. An inherited disorder of coagulation B. Severe liver disease C. Dysfibrinogenemia D. Lupus anticoagulant

    B. Severe liver disease

  • 20

    Fletcher factor (prekallikrein) deficiency may be associated with: A. Bleeding B. Thrombosis C. Thrombocytopenia D. Thrombocytosis

    B. Thrombosis

  • 21

    One of the complications associated with a severe hemophilia A is: A. Hemarthrosis B. Mucous membrane bleeding C. Mild bleeding during surgery D. Immune-mediated thrombocytopenia

    A. Hemarthrosis

  • 22

    The most common subtype of classic von Willebrand’s disease is: A. Type 1 B. Type 2A C. Type 2B D. Type 3

    A. Type 1

  • 23

    A prolonged APTT and PT are corrected when mixed with normal plasma. Which factor is most likely deficient? A. VIII B. V C. XI D. IX

    B. V

  • 24

    Which characteristic describes antithrombin (AT)? A. It is synthesized in megakaryocytes B. It is activated by protein C C. It is a cofactor of heparin D. It is a pathological inhibitor of coagulation

    C. It is a cofactor of heparin

  • 25

    Which laboratory test is affected by heparin therapy? A. Thrombin time B. Fibrinogen assay C. Protein C assay D. Protein S assay

    A. Thrombin time

  • 26

    An abnormal APTT caused by a pathological circulating anticoagulant is: A. Corrected with factor VIII–deficient plasma B. Corrected with factor IX–deficient plasma C. Corrected with normal plasma D. Not corrected with normal plasma

    D. Not corrected with normal plasma

  • 27

    The lupus anticoagulant affects which of the following tests? A. Factor VIII assay B. Factor IX assay C. VWF assay D. Phospholipid-dependent assays

    D. Phospholipid-dependent assays

  • 28

    Which statement about Coumadin (warfarin) is accurate? A. It is a vitamin B antagonist B. It is not recommended for pregnant and lactating women C. It needs antithrombin as a cofactor D. APTT test is used to monitor its dosage

    B. It is not recommended for pregnant and lactating women

  • 29

    Which statement regarding protein C is correct? A. It is a vitamin K–independent zymogen B. It is activated by fibrinogen C. It activates cofactors V and VIII D. Its activity is enhanced by protein S

    D. Its activity is enhanced by protein S

  • 30

    Which of the following is an appropriate screening test for the diagnosis of lupus anticoagulant? A. Thrombin time test B. Diluted Russell’s viper venom test (DRVVT) C. D-dimer test D. FDP test

    B. Diluted Russell’s viper venom test (DRVVT)

  • 31

    Which of the following is most commonly associated with activated protein C resistance (APCR)? A. Bleeding B. Thrombosis C. Epistaxis D. Menorrhagia

    B. Thrombosis

  • 32

    A 50-year-old man has been on heparin for the past 7 days. Which combination of the tests is expected to be abnormal? A. PT and APTT only B. APTT, TT only C. APTT, TT, fibrinogen assay D. PT, APTT, TT

    D. PT, APTT, TT

  • 33

    Which of the following drugs inhibits ADP mediated platelet aggregation? A. Heparin B. Warfarin C. Aspirin D. Prasugrel

    D. Prasugrel

  • 34

    Thrombin-thrombomodulin complex is necessary for activation of: A. Protein C B. Antithrombin C. Protein S D. Factors V and VIII

    A. Protein C

  • 35

    What test is used to monitor heparin therapy? A. INR B. APTT C. TT D. PT

    B. APTT

  • 36

    What test is commonly used to monitor warfarin therapy? A. INR B. APTT C. TT D. Ecarin time

    A. INR

  • 37

    What clotting factors (cofactors) are inhibited by protein S? A. V and X B. Va and VIIIa C. VIII and IX D. VIII and X

    B. Va and VIIIa

  • 38

    Which drug promotes fibrinolysis? A. Warfarin B. Heparin C. Urokinase D. Aspirin

    C. Urokinase

  • 39

    Diagnosis of lupus anticoagulant is confirmed by which of the following criteria? A. Decreased APTT B. Correction of the APPT by mixing studies C. Neutralization of the antibody by high concentration of platelets D. Confirmation that abnormal coagulation tests are time and temperature dependent

    C. Neutralization of the antibody by high concentration of platelets

  • 40

    Which of the following abnormalities is consistent with the presence of lupus anticoagulant? A. Decreased APTT/bleeding complications B. Prolonged APTT/thrombosis C. Prolonged APTT/thrombocytosis D. Thrombocytosis/thrombosis

    B. Prolonged APTT/thrombosis

  • 41

    Which of the following is a characteristic of low molecular weight heparin (LMWH)? A. Generally requires monitoring B. Specifically acts on factor Va C. Has a longer half-life than unfractionated heparin D. Can be used as a fibrinolytic agent

    C. Has a longer half-life than unfractionated heparin

  • 42

    Which of the following tests is most likely to be abnormal in patients taking aspirin? A. Platelet morphology B. Platelet count C. Bleeding time D. Prothrombin time

    C. Bleeding time

  • 43

    Which of the following is associated with antithrombin deficiency? A. Thrombocytosis B. Thrombosis C. Thrombocytopenia D. Bleeding

    B. Thrombosis

  • 44

    Which of the following may be associated with thrombotic events? A. Decreased protein C B. Increased fibrinolysis C. Afibrinogenemia D. ITP

    A. Decreased protein C

  • 45

    Aspirin resistance may be associated with: A. Bleeding B. Factor VIII deficiency C. Thrombosis D. Thrombocytosis

    C. Thrombosis

  • 46

    A prolonged thrombin time is indicative of which of the following antithrombotic therapies? A. Prasugrel B. Clopidogrel C. Aspirin D. Heparin

    D. Heparin

  • 47

    24. Screening tests for thrombophilia should be performed on: A. All pregnant women because of the thrombotic risk B. Patients with a negative family history C. Patients with thrombotic events occurring at a young age D. Patients who are receiving anticoagulant therapy

    C. Patients with thrombotic events occurring at a young age

  • 48

    Prothrombin G20210A is characterized by which of the following causes and conditions? A. Single mutation of prothrombin molecule/ bleeding B. Single mutation of prothrombin molecule/ thrombosis C. Decreased levels of prothrombin in plasma/ thrombosis D. Increased levels of prothrombin in plasma/ bleeding

    B. Single mutation of prothrombin molecule/ thrombosis

  • 49

    Factor V Leiden promotes thrombosis by preventing: A. Deactivation of factor Va B. Activation of factor V C. Activation of protein C D. Activation of protein S

    A. Deactivation of factor Va

  • 50

    What is the approximate incidence of antiphospholipid antibodies in the general population? A. <1% B. 2% C. 10% D. 20%

    B. 2%

  • 51

    Which of the following laboratory tests is helpful in the diagnosis of aspirin resistance? A. APTT B. PT C. Platelet count and morphology D. Platelet aggregation

    D. Platelet aggregation

  • 52

    Which of the following complications may occur as a result of decreased tissue factor pathway inhibitor (TFPI)? A. Increased hemorrhagic episodes B. Increased thrombotic risk C. Impaired platelet plug formation D. Immune thrombocytopenia

    B. Increased thrombotic risk

  • 53

    30. Factor VIII inhibitors occur in ____________ of patients with factor VIII deficiency? A. 40%–50% B. 30%–40% C. 25%–30% D. 10%–20%

    D. 10%–20%

  • 54

    Which therapy and resulting mode of action are appropriate for the treatment of a patient with a high titer of factor VIII inhibitors? A. Factor VIII concentrate to neutralize the antibodies B. Recombinant factor VIIa (rVIIa) to activate factor X C. Factor X concentrate to activate the common pathway D. Fresh frozen plasma to replace factor VIII

    B. Recombinant factor VIIa (rVIIa) to activate factor X

  • 55

    The Bethesda assay is used for which determination? A. Lupus anticoagulant titer B. Factor VIII inhibitor titer C. Factor V Leiden titer D. Protein S deficiency

    B. Factor VIII inhibitor titer

  • 56

    Hyperhomocysteinemia may be a risk factor for: A. Bleeding B. Thrombocythemia C. Thrombosis D. Thrombocytopenia

    C. Thrombosis

  • 57

    Which drug may be associated with deep venous thrombosis (DVT)? A. Aspirin B. tPA C. Oral contraceptives D. Plavix (clopidogrel)

    A. Aspirin

  • 58

    Argatroban may be used as an anticoagulant drug in patients with: A. DVT B. Hemorrhage C. TTP D. Thrombocytosis

    A. DVT

  • 59

    Heparin-induced thrombocytopenia (HIT) results from: A. Antibodies to heparin B. Antibodies to platelets C. Antibodies to PF4 D. Antibodies to heparin-PF4 complex

    D. Antibodies to heparin-PF4 complex

  • 60

    Which laboratory test is used to screen for activated protein C resistance? A. Mixing studies with normal plasma B. Mixing studies with factor-deficient plasma C. Modified APTT with and without activated protein C D. Modified PT with and without activated protein C

    C. Modified APTT with and without activated protein C

  • 61

    Ecarin clotting time may be used to monitor: A. Heparin therapy B. Warfarin therapy C. Fibrinolytic therapy D. Hirudin therapy

    D. Hirudin therapy

  • 62

    Which of the following may interfere with the activated protein C resistance (APCR) screening test? A. Lupus anticoagulant B. Protein C deficiency C. Antithrombin deficiency D. Protein S deficiency

    A. Lupus anticoagulant

  • 63

    Thrombophilia may be associated with which of the following disorders? A. Afibrinogenemia B. Hypofibrinogenemia C. Factor VIII inhibitor D. Hyperfibrinogenemia

    D. Hyperfibrinogenemia

  • 64

    Which of the following anticoagulant drugs can be used in patients with HIT? A. Warfarin B. Heparin C. Aspirin D. Lepirudin

    D. Lepirudin

  • 65

    Which of the following is the preferred method to monitor heparin therapy at the point of care during cardiac surgery? A. APTT B. Activated clotting time test (ACT) C. PT D. TT

    B. Activated clotting time test (ACT)

  • 66

    Mrs. Smith has the following laboratory results, and no bleeding history: APTT: prolonged APTT results on a 1:1 mixture of the patient’s plasma with normal plasma: Preincubation: prolonged APTT 2-hour incubation: prolonged APTT These results are consistent with: A. Factor VIII deficiency B. Factor VIII inhibitor C. Lupus anticoagulant D. Protein C deficiency

    C. Lupus anticoagulant

  • 67

    Which test may be used to monitor LMWH therapy? A. APTT B. INR C. Anti-Xa heparin assay D. Activated clotting time

    C. Anti-Xa heparin assay

  • 68

    Patient History A 3-year-old male was admitted to a hospital with scattered petechiae and epistaxis. The patient had normal growth and had no other medical problems except for chickenpox 3 weeks earlier. His family history was unremarkable. These clinical manifestations and laboratory results are consistent with which condition? A. TTP B. DIC C. ITP D. HUS

    C. ITP

  • 69

    The following results are obtained from a patient who developed severe bleeding: Prolonged PT and APTT Platelet count = 100 × 109 /L Fibrinogen = 40 mg/dL Which of the following blood products should be recommended for transfusion? A. Factor VIII concentrate B. Platelets C. Fresh frozen plasma D. Cryoprecipitate

    D. Cryoprecipitate

  • 70

    A 30-year-old woman develops signs and symptoms of thrombosis in her left lower leg following 5 days of heparin therapy. The patient had open-heart surgery 3 days previously and has been on heparin ever since. Which of the following would be the most helpful in making the diagnosis? A. Fibrinogen assay B. Prothrombin time C. Platelet counts D. Increased heparin dose

    C. Platelet counts

  • 71

    The following laboratory results were obtained on a 25-year-old woman with menorrhagia after delivery of her second son. The patient has no previous bleeding history. Normal platelet count; normal bleeding time; normal PT; prolonged APTT Mixing of the patient’s plasma with normal plasma corrected the prolonged APTT on immediate testing. However, mixing followed by 2-hour incubation at 37°C caused a prolonged APTT. What is the most probable cause of these laboratory results? A. Lupus anticoagulant B. Factor VIII deficiency C. Factor IX deficiency D. Factor VIII inhibitor

    D. Factor VIII inhibitor

  • 72

    A 62-year-old female presents with jaundice and the following laboratory data: Peripheral blood smear: macrocytosis, target cells Platelet count: 355 × 109/L PT: 25 sec (reference range =10–14) APTT: 65 sec (reference range = 28–36) Transaminases: elevated (AST:ALT>1) Total and direct bilirubin: elevated These clinical presentations and laboratory results are consistent with: A. Inherited factor VII deficiency B. DIC C. Cirrhosis of the liver D. von Willebrand’s disease

    C. Cirrhosis of the liver

  • 73

    When performing a mixing study, the patient’s APTT is corrected to 12% of normal. What is the most appropriate interpretation of these findings? A. The APTT is considered corrected B. The APTT is considered uncorrected C. The mixing study needs to be repeated D. A circulating anticoagulant can be ruled out

    C. The mixing study needs to be repeated

  • 74

    A standard blue-top tube filled appropriately (with 4.5 mL blood) was submitted to the laboratory for preoperative PT and APTT testing. The results of both tests were elevated. The patient’s PT and APTT from the previous day were within normal limits, and he is not on heparin therapy. Which is the most appropriate first step to investigate the abnormal results? A. Report the result as obtained B. Perform a mixing study C. Check the sample for a clot D. Report the APTT only

    C. Check the sample for a clot

  • 75

    A plasma sample submitted to the lab for PT testing has been stored for 25 hours at 4°C. The PT result is shortened. What is the most probable cause? A. Factor VII deficiency B. Activation of factor VII due to exposure to cold temperature C. Lupus inhibitor D. Factor X inhibitor

    B. Activation of factor VII due to exposure to cold temperature

  • 76

    The APTT results are not elevated in a patient receiving heparin. Which of the following factors may be associated with the lack of response to heparin therapy in this patient? A. Protein C deficiency B. Antithrombin deficiency C. Protein S deficiency D. Factor VIII deficiency

    B. Antithrombin deficiency

  • 77

    A 50-year-old patient was admitted to the emergency department complaining of pain in her right leg. Her leg was red, swollen, and warm to the touch. Deep venous thrombosis was suspected, and the patient was started on heparin therapy. Which of the following is (are) the proper protocol to evaluate patients receiving heparin therapy? A. A baseline APTT and platelet count; APTT testing every 6 hours until the target is reached B. Repeat APTT after 5 days postheparin therapy to adjust the therapeutic dose C. Monitor the platelet count daily and every other day after heparin therapy is completed D. Monitor PT daily to adjust the therapeutic dose

    A. A baseline APTT and platelet count; APTT testing every 6 hours until the target is reached

  • 78

    A 60-year-old patient was admitted to a hospital for a liver biopsy. The biopsy was scheduled for 11:00 a.m. The coagulation results performed at the time of admission revealed a prolonged PT with an INR of 4.5. What is the physician’s most appropriate course of action? A. Proceed with biopsy, because a prolonged PT is expected in liver disease B. Postpone the procedure for a couple of days C. Cancel the procedure and start the patient on vitamin K therapy D. Put patient on vitamin K and proceed with the procedure immediately

    C. Cancel the procedure and start the patient on vitamin K therapy

  • 79

    A fresh blood sample was sent to the laboratory at 8:00 a.m. for a PT test. At 4:00 p.m., the doctor requested an APTT test to be done on the same sample. What should the technologist do? A. Rerun APTT on the 8:00 a.m. sample and report the result B. Request a new sample for APTT C. Run APTT in duplicate and report the average D. Mix the patient plasma with normal plasma and run the APTT

    B. Request a new sample for APTT

  • 80

    An APTT test is performed on a patient and the result is 50 sec (reference range 27–37 sec). The instrument flags the result owing to failure of the delta check. The patient had an APTT of 35 sec the previous day. The technologist calls the nursing unit to check whether the patient is on heparin therapy. The patient is not receiving heparin. What is the next appropriate step? A. Check the family history for an inherited factor VIII deficiency B. Check to see if the patient has received any other anticoagulant medications C. Perform mixing studies D. Perform a factor VIII assay

    B. Check to see if the patient has received any other anticoagulant medications

  • 81

    A patient was put on heparin therapy postoperatively for prevention of thrombosis. The patient had the following laboratory results on admission: Platelet count = 350 × 109/L; PT = 12 sec (reference: 10–13 sec); APTT = 35 sec (reference: 28–37). After 6 days of heparin therapy, the patient complained of pain and swelling in her left leg. Her platelet count dropped to 85 × 109/L and her APTT result was 36 sec. The physician suspected heparin-induced thrombocytopenia (HIT) and ordered a platelet aggregation test to be performed immediately. The heparin-induced platelet aggregation test result was negative. Heparin therapy was continued. Several days later, the patient developed a massive clot in her left leg that necessitated amputation. Which of the following should have been recognized or initiated? A. The patient should have been placed on LMWH B. The heparin dose should have been increased C. The negative platelet aggregation does not rule out HIT D. The patient should have been placed on warfarin therapy

    C. The negative platelet aggregation does not rule out HIT

  • 82

    A 50-year-old female was admitted to a hospital for hip replacement surgery. The preoperative tests were performed and the results showed an Hgb of 13.5 g/dL; Hct = 42%; PT = 12 sec; APTT = 36 sec. The patient was bleeding during surgery and the postoperative test results revealed an Hgb = 5.0 g/dL; Hct = 16%; PT = 8 sec; and APTT = 25 sec. What steps should be taken before releasing these results? A. No follow-up steps are needed; report the results as obtained B. Report Hgb and Hct results, adjust the anticoagulant volume, and redraw a new sample for PT and APTT C. Call the nurse and ask if the patient is receiving heparin D. Because the patient is severely anemic, multiply the PT and APTT results by two and report the results

    B. Report Hgb and Hct results, adjust the anticoagulant volume, and redraw a new sample for PT and APTT

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Which of the following platelet aggregating agents demonstrates a monophasic aggregation curve when used in optimal concentration? A. Thrombin B. Collagen C. Adenosine diphosphate (ADP) D. Epinephrine

    B. Collagen

  • 2

    The APTT is sensitive to a deficiency of which clotting factor? A. Factor VII B. Factor X C. PF3 D. Calcium

    B. Factor X

  • 3

    Which test result would be normal in a patient with dysfibrinogenemia? A. Thrombin time B. APTT C. PT D. Immunologic fibrinogen level

    D. Immunologic fibrinogen level

  • 4

    A patient with a prolonged PT is given intravenous vitamin K. The PT corrects to normal after 24 hours. What clinical condition most likely caused these results? A. Necrotic liver disease B. Factor X deficiency C. Fibrinogen deficiency D. Obstructive jaundice

    D. Obstructive jaundice

  • 5

    Which factor deficiency is associated with a prolonged PT and APTT? A. X B. VIII C. IX D. XI

    A. X

  • 6

    A prolonged APTT is corrected with factor VIII– deficient plasma but not with factor IX–deficient plasma. Which factor is deficient? A. V B. VIII C. IX D. X

    C. IX

  • 7

    6. Which of the following is a characteristic of classic hemophilia A? A. Prolonged bleeding time B. Autosomal recessive inheritance C. Mild to severe bleeding episodes D. Prolonged PT

    C. Mild to severe bleeding episodes

  • 8

    Refer to the following results: PT = prolonged APTT = prolonged Platelet count = decreased Which disorder may be indicated? A. Factor VIII deficiency B. von Willebrand’s disease C. DIC D. Factor IX deficiency

    C. DIC

  • 9

    Which of the following is a predisposing condition for the development of DIC? A. Adenocarcinoma B. Idiopathic thrombocytopenic purpura (ITP) C. Post-transfusion purpura (PTP) D. Heparin-induced thrombocytopenia (HIT)

    A. Adenocarcinoma

  • 10

    Factor XII deficiency is associated with: A. Bleeding episodes B. Epistaxis C. Decreased risk of thrombosis D. Increased risk of thrombosis

    D. Increased risk of thrombosis

  • 11

    The following results were obtained on a patient: normal platelet count and function, normal PT, and prolonged APTT. Which of the following disorders is most consistent with these results? A. Hemophilia A B. Bernard–Soulier syndrome C. von Willebrand’s disease D. Glanzmann’s thrombasthenia

    A. Hemophilia A

  • 12

    The following laboratory results were obtained from a 40-year-old woman: PT = 20 sec; APTT = 50 sec; thrombin time = 18 sec. What is the most probable diagnosis? A. Factor VII deficiency B. Factor VIII deficiency C. Factor X deficiency D. Hypofibrinogenemia

    D. Hypofibrinogenemia

  • 13

    When performing a factor VIII activity assay, a patient’s plasma is mixed with: A. Normal patient’s plasma B. Factor VIII deficient plasma C. Plasma with a high concentration of factor VIII D. Normal control plasma

    B. Factor VIII deficient plasma

  • 14

    The most suitable product for treatment of factor VIII deficiency is: A. Fresh frozen plasma B. Factor VIII concentrate C. Prothrombin complex concentrate D. Factor V Leiden

    C. Prothrombin complex concentrate

  • 15

    Which of the following is associated with an abnormal platelet aggregation test? A. Factor VIII deficiency B. Factor VIII inhibitor C. Lupus anticoagulant D. Afibrinogenemia

    D. Afibrinogenemia

  • 16

    Refer to the following results: PT = normal APTT = prolonged Bleeding time= increased Platelet count = normal Platelet aggregation to ristocetin = abnormal Which of the following disorders may be indicated? A. Factor VIII deficiency B. DIC C. von Willebrand’s disease D. Factor IX deficiency

    C. von Willebrand’s disease

  • 17

    Which results are associated with hemophilia A? A. Prolonged APTT, normal PT B. Prolonged PT and APTT C. Prolonged PT, normal APTT D. Normal PT and APTT

    A. Prolonged APTT, normal PT

  • 18

    Fibrin monomers are increased in which of the following conditions? A. Primary fibrinolysis B. DIC C. Factor VIII deficiency D. Fibrinogen deficiency

    B. DIC

  • 19

    Which of the following is associated with multiple factor deficiencies? A. An inherited disorder of coagulation B. Severe liver disease C. Dysfibrinogenemia D. Lupus anticoagulant

    B. Severe liver disease

  • 20

    Fletcher factor (prekallikrein) deficiency may be associated with: A. Bleeding B. Thrombosis C. Thrombocytopenia D. Thrombocytosis

    B. Thrombosis

  • 21

    One of the complications associated with a severe hemophilia A is: A. Hemarthrosis B. Mucous membrane bleeding C. Mild bleeding during surgery D. Immune-mediated thrombocytopenia

    A. Hemarthrosis

  • 22

    The most common subtype of classic von Willebrand’s disease is: A. Type 1 B. Type 2A C. Type 2B D. Type 3

    A. Type 1

  • 23

    A prolonged APTT and PT are corrected when mixed with normal plasma. Which factor is most likely deficient? A. VIII B. V C. XI D. IX

    B. V

  • 24

    Which characteristic describes antithrombin (AT)? A. It is synthesized in megakaryocytes B. It is activated by protein C C. It is a cofactor of heparin D. It is a pathological inhibitor of coagulation

    C. It is a cofactor of heparin

  • 25

    Which laboratory test is affected by heparin therapy? A. Thrombin time B. Fibrinogen assay C. Protein C assay D. Protein S assay

    A. Thrombin time

  • 26

    An abnormal APTT caused by a pathological circulating anticoagulant is: A. Corrected with factor VIII–deficient plasma B. Corrected with factor IX–deficient plasma C. Corrected with normal plasma D. Not corrected with normal plasma

    D. Not corrected with normal plasma

  • 27

    The lupus anticoagulant affects which of the following tests? A. Factor VIII assay B. Factor IX assay C. VWF assay D. Phospholipid-dependent assays

    D. Phospholipid-dependent assays

  • 28

    Which statement about Coumadin (warfarin) is accurate? A. It is a vitamin B antagonist B. It is not recommended for pregnant and lactating women C. It needs antithrombin as a cofactor D. APTT test is used to monitor its dosage

    B. It is not recommended for pregnant and lactating women

  • 29

    Which statement regarding protein C is correct? A. It is a vitamin K–independent zymogen B. It is activated by fibrinogen C. It activates cofactors V and VIII D. Its activity is enhanced by protein S

    D. Its activity is enhanced by protein S

  • 30

    Which of the following is an appropriate screening test for the diagnosis of lupus anticoagulant? A. Thrombin time test B. Diluted Russell’s viper venom test (DRVVT) C. D-dimer test D. FDP test

    B. Diluted Russell’s viper venom test (DRVVT)

  • 31

    Which of the following is most commonly associated with activated protein C resistance (APCR)? A. Bleeding B. Thrombosis C. Epistaxis D. Menorrhagia

    B. Thrombosis

  • 32

    A 50-year-old man has been on heparin for the past 7 days. Which combination of the tests is expected to be abnormal? A. PT and APTT only B. APTT, TT only C. APTT, TT, fibrinogen assay D. PT, APTT, TT

    D. PT, APTT, TT

  • 33

    Which of the following drugs inhibits ADP mediated platelet aggregation? A. Heparin B. Warfarin C. Aspirin D. Prasugrel

    D. Prasugrel

  • 34

    Thrombin-thrombomodulin complex is necessary for activation of: A. Protein C B. Antithrombin C. Protein S D. Factors V and VIII

    A. Protein C

  • 35

    What test is used to monitor heparin therapy? A. INR B. APTT C. TT D. PT

    B. APTT

  • 36

    What test is commonly used to monitor warfarin therapy? A. INR B. APTT C. TT D. Ecarin time

    A. INR

  • 37

    What clotting factors (cofactors) are inhibited by protein S? A. V and X B. Va and VIIIa C. VIII and IX D. VIII and X

    B. Va and VIIIa

  • 38

    Which drug promotes fibrinolysis? A. Warfarin B. Heparin C. Urokinase D. Aspirin

    C. Urokinase

  • 39

    Diagnosis of lupus anticoagulant is confirmed by which of the following criteria? A. Decreased APTT B. Correction of the APPT by mixing studies C. Neutralization of the antibody by high concentration of platelets D. Confirmation that abnormal coagulation tests are time and temperature dependent

    C. Neutralization of the antibody by high concentration of platelets

  • 40

    Which of the following abnormalities is consistent with the presence of lupus anticoagulant? A. Decreased APTT/bleeding complications B. Prolonged APTT/thrombosis C. Prolonged APTT/thrombocytosis D. Thrombocytosis/thrombosis

    B. Prolonged APTT/thrombosis

  • 41

    Which of the following is a characteristic of low molecular weight heparin (LMWH)? A. Generally requires monitoring B. Specifically acts on factor Va C. Has a longer half-life than unfractionated heparin D. Can be used as a fibrinolytic agent

    C. Has a longer half-life than unfractionated heparin

  • 42

    Which of the following tests is most likely to be abnormal in patients taking aspirin? A. Platelet morphology B. Platelet count C. Bleeding time D. Prothrombin time

    C. Bleeding time

  • 43

    Which of the following is associated with antithrombin deficiency? A. Thrombocytosis B. Thrombosis C. Thrombocytopenia D. Bleeding

    B. Thrombosis

  • 44

    Which of the following may be associated with thrombotic events? A. Decreased protein C B. Increased fibrinolysis C. Afibrinogenemia D. ITP

    A. Decreased protein C

  • 45

    Aspirin resistance may be associated with: A. Bleeding B. Factor VIII deficiency C. Thrombosis D. Thrombocytosis

    C. Thrombosis

  • 46

    A prolonged thrombin time is indicative of which of the following antithrombotic therapies? A. Prasugrel B. Clopidogrel C. Aspirin D. Heparin

    D. Heparin

  • 47

    24. Screening tests for thrombophilia should be performed on: A. All pregnant women because of the thrombotic risk B. Patients with a negative family history C. Patients with thrombotic events occurring at a young age D. Patients who are receiving anticoagulant therapy

    C. Patients with thrombotic events occurring at a young age

  • 48

    Prothrombin G20210A is characterized by which of the following causes and conditions? A. Single mutation of prothrombin molecule/ bleeding B. Single mutation of prothrombin molecule/ thrombosis C. Decreased levels of prothrombin in plasma/ thrombosis D. Increased levels of prothrombin in plasma/ bleeding

    B. Single mutation of prothrombin molecule/ thrombosis

  • 49

    Factor V Leiden promotes thrombosis by preventing: A. Deactivation of factor Va B. Activation of factor V C. Activation of protein C D. Activation of protein S

    A. Deactivation of factor Va

  • 50

    What is the approximate incidence of antiphospholipid antibodies in the general population? A. <1% B. 2% C. 10% D. 20%

    B. 2%

  • 51

    Which of the following laboratory tests is helpful in the diagnosis of aspirin resistance? A. APTT B. PT C. Platelet count and morphology D. Platelet aggregation

    D. Platelet aggregation

  • 52

    Which of the following complications may occur as a result of decreased tissue factor pathway inhibitor (TFPI)? A. Increased hemorrhagic episodes B. Increased thrombotic risk C. Impaired platelet plug formation D. Immune thrombocytopenia

    B. Increased thrombotic risk

  • 53

    30. Factor VIII inhibitors occur in ____________ of patients with factor VIII deficiency? A. 40%–50% B. 30%–40% C. 25%–30% D. 10%–20%

    D. 10%–20%

  • 54

    Which therapy and resulting mode of action are appropriate for the treatment of a patient with a high titer of factor VIII inhibitors? A. Factor VIII concentrate to neutralize the antibodies B. Recombinant factor VIIa (rVIIa) to activate factor X C. Factor X concentrate to activate the common pathway D. Fresh frozen plasma to replace factor VIII

    B. Recombinant factor VIIa (rVIIa) to activate factor X

  • 55

    The Bethesda assay is used for which determination? A. Lupus anticoagulant titer B. Factor VIII inhibitor titer C. Factor V Leiden titer D. Protein S deficiency

    B. Factor VIII inhibitor titer

  • 56

    Hyperhomocysteinemia may be a risk factor for: A. Bleeding B. Thrombocythemia C. Thrombosis D. Thrombocytopenia

    C. Thrombosis

  • 57

    Which drug may be associated with deep venous thrombosis (DVT)? A. Aspirin B. tPA C. Oral contraceptives D. Plavix (clopidogrel)

    A. Aspirin

  • 58

    Argatroban may be used as an anticoagulant drug in patients with: A. DVT B. Hemorrhage C. TTP D. Thrombocytosis

    A. DVT

  • 59

    Heparin-induced thrombocytopenia (HIT) results from: A. Antibodies to heparin B. Antibodies to platelets C. Antibodies to PF4 D. Antibodies to heparin-PF4 complex

    D. Antibodies to heparin-PF4 complex

  • 60

    Which laboratory test is used to screen for activated protein C resistance? A. Mixing studies with normal plasma B. Mixing studies with factor-deficient plasma C. Modified APTT with and without activated protein C D. Modified PT with and without activated protein C

    C. Modified APTT with and without activated protein C

  • 61

    Ecarin clotting time may be used to monitor: A. Heparin therapy B. Warfarin therapy C. Fibrinolytic therapy D. Hirudin therapy

    D. Hirudin therapy

  • 62

    Which of the following may interfere with the activated protein C resistance (APCR) screening test? A. Lupus anticoagulant B. Protein C deficiency C. Antithrombin deficiency D. Protein S deficiency

    A. Lupus anticoagulant

  • 63

    Thrombophilia may be associated with which of the following disorders? A. Afibrinogenemia B. Hypofibrinogenemia C. Factor VIII inhibitor D. Hyperfibrinogenemia

    D. Hyperfibrinogenemia

  • 64

    Which of the following anticoagulant drugs can be used in patients with HIT? A. Warfarin B. Heparin C. Aspirin D. Lepirudin

    D. Lepirudin

  • 65

    Which of the following is the preferred method to monitor heparin therapy at the point of care during cardiac surgery? A. APTT B. Activated clotting time test (ACT) C. PT D. TT

    B. Activated clotting time test (ACT)

  • 66

    Mrs. Smith has the following laboratory results, and no bleeding history: APTT: prolonged APTT results on a 1:1 mixture of the patient’s plasma with normal plasma: Preincubation: prolonged APTT 2-hour incubation: prolonged APTT These results are consistent with: A. Factor VIII deficiency B. Factor VIII inhibitor C. Lupus anticoagulant D. Protein C deficiency

    C. Lupus anticoagulant

  • 67

    Which test may be used to monitor LMWH therapy? A. APTT B. INR C. Anti-Xa heparin assay D. Activated clotting time

    C. Anti-Xa heparin assay

  • 68

    Patient History A 3-year-old male was admitted to a hospital with scattered petechiae and epistaxis. The patient had normal growth and had no other medical problems except for chickenpox 3 weeks earlier. His family history was unremarkable. These clinical manifestations and laboratory results are consistent with which condition? A. TTP B. DIC C. ITP D. HUS

    C. ITP

  • 69

    The following results are obtained from a patient who developed severe bleeding: Prolonged PT and APTT Platelet count = 100 × 109 /L Fibrinogen = 40 mg/dL Which of the following blood products should be recommended for transfusion? A. Factor VIII concentrate B. Platelets C. Fresh frozen plasma D. Cryoprecipitate

    D. Cryoprecipitate

  • 70

    A 30-year-old woman develops signs and symptoms of thrombosis in her left lower leg following 5 days of heparin therapy. The patient had open-heart surgery 3 days previously and has been on heparin ever since. Which of the following would be the most helpful in making the diagnosis? A. Fibrinogen assay B. Prothrombin time C. Platelet counts D. Increased heparin dose

    C. Platelet counts

  • 71

    The following laboratory results were obtained on a 25-year-old woman with menorrhagia after delivery of her second son. The patient has no previous bleeding history. Normal platelet count; normal bleeding time; normal PT; prolonged APTT Mixing of the patient’s plasma with normal plasma corrected the prolonged APTT on immediate testing. However, mixing followed by 2-hour incubation at 37°C caused a prolonged APTT. What is the most probable cause of these laboratory results? A. Lupus anticoagulant B. Factor VIII deficiency C. Factor IX deficiency D. Factor VIII inhibitor

    D. Factor VIII inhibitor

  • 72

    A 62-year-old female presents with jaundice and the following laboratory data: Peripheral blood smear: macrocytosis, target cells Platelet count: 355 × 109/L PT: 25 sec (reference range =10–14) APTT: 65 sec (reference range = 28–36) Transaminases: elevated (AST:ALT>1) Total and direct bilirubin: elevated These clinical presentations and laboratory results are consistent with: A. Inherited factor VII deficiency B. DIC C. Cirrhosis of the liver D. von Willebrand’s disease

    C. Cirrhosis of the liver

  • 73

    When performing a mixing study, the patient’s APTT is corrected to 12% of normal. What is the most appropriate interpretation of these findings? A. The APTT is considered corrected B. The APTT is considered uncorrected C. The mixing study needs to be repeated D. A circulating anticoagulant can be ruled out

    C. The mixing study needs to be repeated

  • 74

    A standard blue-top tube filled appropriately (with 4.5 mL blood) was submitted to the laboratory for preoperative PT and APTT testing. The results of both tests were elevated. The patient’s PT and APTT from the previous day were within normal limits, and he is not on heparin therapy. Which is the most appropriate first step to investigate the abnormal results? A. Report the result as obtained B. Perform a mixing study C. Check the sample for a clot D. Report the APTT only

    C. Check the sample for a clot

  • 75

    A plasma sample submitted to the lab for PT testing has been stored for 25 hours at 4°C. The PT result is shortened. What is the most probable cause? A. Factor VII deficiency B. Activation of factor VII due to exposure to cold temperature C. Lupus inhibitor D. Factor X inhibitor

    B. Activation of factor VII due to exposure to cold temperature

  • 76

    The APTT results are not elevated in a patient receiving heparin. Which of the following factors may be associated with the lack of response to heparin therapy in this patient? A. Protein C deficiency B. Antithrombin deficiency C. Protein S deficiency D. Factor VIII deficiency

    B. Antithrombin deficiency

  • 77

    A 50-year-old patient was admitted to the emergency department complaining of pain in her right leg. Her leg was red, swollen, and warm to the touch. Deep venous thrombosis was suspected, and the patient was started on heparin therapy. Which of the following is (are) the proper protocol to evaluate patients receiving heparin therapy? A. A baseline APTT and platelet count; APTT testing every 6 hours until the target is reached B. Repeat APTT after 5 days postheparin therapy to adjust the therapeutic dose C. Monitor the platelet count daily and every other day after heparin therapy is completed D. Monitor PT daily to adjust the therapeutic dose

    A. A baseline APTT and platelet count; APTT testing every 6 hours until the target is reached

  • 78

    A 60-year-old patient was admitted to a hospital for a liver biopsy. The biopsy was scheduled for 11:00 a.m. The coagulation results performed at the time of admission revealed a prolonged PT with an INR of 4.5. What is the physician’s most appropriate course of action? A. Proceed with biopsy, because a prolonged PT is expected in liver disease B. Postpone the procedure for a couple of days C. Cancel the procedure and start the patient on vitamin K therapy D. Put patient on vitamin K and proceed with the procedure immediately

    C. Cancel the procedure and start the patient on vitamin K therapy

  • 79

    A fresh blood sample was sent to the laboratory at 8:00 a.m. for a PT test. At 4:00 p.m., the doctor requested an APTT test to be done on the same sample. What should the technologist do? A. Rerun APTT on the 8:00 a.m. sample and report the result B. Request a new sample for APTT C. Run APTT in duplicate and report the average D. Mix the patient plasma with normal plasma and run the APTT

    B. Request a new sample for APTT

  • 80

    An APTT test is performed on a patient and the result is 50 sec (reference range 27–37 sec). The instrument flags the result owing to failure of the delta check. The patient had an APTT of 35 sec the previous day. The technologist calls the nursing unit to check whether the patient is on heparin therapy. The patient is not receiving heparin. What is the next appropriate step? A. Check the family history for an inherited factor VIII deficiency B. Check to see if the patient has received any other anticoagulant medications C. Perform mixing studies D. Perform a factor VIII assay

    B. Check to see if the patient has received any other anticoagulant medications

  • 81

    A patient was put on heparin therapy postoperatively for prevention of thrombosis. The patient had the following laboratory results on admission: Platelet count = 350 × 109/L; PT = 12 sec (reference: 10–13 sec); APTT = 35 sec (reference: 28–37). After 6 days of heparin therapy, the patient complained of pain and swelling in her left leg. Her platelet count dropped to 85 × 109/L and her APTT result was 36 sec. The physician suspected heparin-induced thrombocytopenia (HIT) and ordered a platelet aggregation test to be performed immediately. The heparin-induced platelet aggregation test result was negative. Heparin therapy was continued. Several days later, the patient developed a massive clot in her left leg that necessitated amputation. Which of the following should have been recognized or initiated? A. The patient should have been placed on LMWH B. The heparin dose should have been increased C. The negative platelet aggregation does not rule out HIT D. The patient should have been placed on warfarin therapy

    C. The negative platelet aggregation does not rule out HIT

  • 82

    A 50-year-old female was admitted to a hospital for hip replacement surgery. The preoperative tests were performed and the results showed an Hgb of 13.5 g/dL; Hct = 42%; PT = 12 sec; APTT = 36 sec. The patient was bleeding during surgery and the postoperative test results revealed an Hgb = 5.0 g/dL; Hct = 16%; PT = 8 sec; and APTT = 25 sec. What steps should be taken before releasing these results? A. No follow-up steps are needed; report the results as obtained B. Report Hgb and Hct results, adjust the anticoagulant volume, and redraw a new sample for PT and APTT C. Call the nurse and ask if the patient is receiving heparin D. Because the patient is severely anemic, multiply the PT and APTT results by two and report the results

    B. Report Hgb and Hct results, adjust the anticoagulant volume, and redraw a new sample for PT and APTT